Topical Cannabinoids and Ocular Pain Relief

 

Topical Cannabinoids and Ocular Pain Relief

Endocannabinoid system (ECS) modulation has been observed to have a wide range of potential therapeutic benefits for multiple disorders, including ocular pain

Dr. Faktorovich | | 4 min read | Opinion

Headshot supplied by Dr. Ella Faktorovich

Though a number of different treatment options exist, safe and effective management of ocular pain remains a challenge. This year marks 60 years since the identification of the structure of two major cannabinoids – THC and CBD (

1
). This advance set in motion a series of discoveries leading to identification of the endocannabinoid system (ECS). This intricate signaling ystem of molecules, receptors, and enzymes is present in nearly all organs, including the eye, and ECS modulation has been observed to have a wide range of potential therapeutic benefits for multiple disorders, including ocular pain (
2
). Coupled with advances in drug delivery systems, ECS modulators have the potential to provide localized ophthalmic drug delivery that avoids systemic effects.

Both topical and systemic analgesics can effectively relieve acute ocular pain, but they have marked limitations in terms of their safety profile (
3
). For example, topical anesthetics and non-steroidal anti-inflammatory drugs (NSAIDs) may delay epithelial healing, whereas systemic gabapentinoids and opioids have been shown to lead to sedation and respiratory depression.

Treatment of chronic ocular pain can present an even greater challenge. This pain may accompany a chronic disease state, such as dry eye disease (DED) or diabetes, and though treatment of the underlying disease is essential, neuronal sensitization can still persist even when the disease is brought under control. Treatment options for chronic neuropathic pain include oral gabapentinoids, opioids, and tricyclic antidepressants. However, their efficacy is limited and the side effects may not be acceptable.

“ECS localization in the eye and on the neutrophils that may infiltrate the eye during inflammation”

There are three essential components of the ocular ECS: receptors, endogenous cannabinoids, and enzymes responsible for synthesis and degradation of receptors and cannabinoids. Acting to regulate pain transmission, cannabinoid 1 receptor (CB1R) has been identified throughout ocular tissues, whereas the cannabinoid 2 receptor (CB2R) is primarily localized to the surface of immune cells (

3
). Since ocular inflammation can result in both acute and chronic pain, the anti-inflammatory actions of CB2R modulation can have an indirect effect on improving ocular comfort. Reducing the release of noxious inflammatory mediators helps ameliorate acute pain, and prevention of neuronal sensitization by these mediators reduces the possibility of developing chronic neuropathic pain.

Since pain and inflammation often accompany DED, topical cannabinoids could also represent an important therapeutic approach to this condition. Because CB1R is present on the corneal epithelium, topical cannabinoids can easily access a desiccated epithelium – which can be a source of both acute and chronic ocular pain for DED patients – providing significant pain relief.

Interestingly, CB1R is also expressed in neurons innervating the lacrimal gland. Usually the expression is low, but this expression increases during DED-associated inflammation. McDowell et. al highlighted how CB1R activation reduces sensitization of lacrimal gland nerves, potentially reducing chronic neurotrophic pain (
4
). Tran et. al also demonstrated improvement in corneal fluorescence, and reduction of corneal and conjunctival inflammation after topical application of cannabinoids in experimentally induced dry eye models (
5
).

Other methods of ECS modulation are currently under investigation. One uses modulators that increase the binding affinity of cannabinoids to the receptors, allowing for a smaller dose of cannabinoid to achieve the desired effect; another method uses enzyme inhibitors that increase levels of endocannabinoids by inhibiting the actions of enzymes that degrade them. Treatment with enzyme inhibitors has been shown to reduce pain and inflammation in several preclinical models, including for chronic neuropathic pain (
3
).

There are challenges though; ECS modulators are hydrophobic, so the potential bottleneck of ocular penetration and bioavailability needs to be considered; here, nanotechnology-based drug delivery methods may prove useful.

The ubiquitous presence of the endocannabinoid system in ocular tissues, its role in ocular analgesia, and its demonstrated responsiveness to topical modulators represent a unique opportunity to continue developing a novel class of ECS ocular pain relief medications. These medications could either be used alone or in conjunction with other ocular analgesics to optimize ocular comfort, relieving both acute and chronic pain for patients.

Comments

Post a Comment

Popular posts from this blog

Chiari Malformation

Image
Chiari malformation is a neurological condition where the brain's cerebellum extends into the spinal canal, putting pressure on the brain and spine. Here is an overview: Types: 1. Chiari I: Most common, cerebellum extends into spinal canal 2. Chiari II: More severe, brain stem and cerebellum extend into spinal canal 3. Chiari III: Rare, cerebellum and brain stem extend through an opening in the skull 4. Chiari IV: Rare, cerebellum doesn't develop properly.   Symptoms: 1. Headaches 2. Neck pain 3. Dizziness or balance problems 4. Numbness or tingling in hands and feet 5. Vision problems 6. Hearing loss 7. Swallowing difficulties 8. Fatigue Causes: 1. Congenital (present at birth) 2. Genetic mutations 3. Spinal injury or trauma 4. Infections like meningitis 5. Tumors or cysts   Treatment: 1. Surgery to relieve pressure and decompress the spinal cord 2. Posterior fossa decompression 3. Duraplasty (expanding the dura mater) 4. Laminectomy (removing part of the vertebra) 5. Physical
Read more

Pulmonary Vascular Disease

Image
  The definition of pulmonary vascular disease is simply: any condition that affects the   blood   vessels along the route between the   heart   and   lungs . Blood travels from the  heart , to the lungs, and back to the heart. This process continually refills the blood with oxygen, and allows carbon dioxide be exhaled. Here's how the process works: Oxygen-poor blood returns from the body's tissues through the veins back to the right side of the heart. The right heart pumps oxygen-poor blood through the pulmonary  arteries  into the lungs. This blood becomes filled with oxygen. The oxygen-rich blood returns from the lungs back to the left side of the heart. The left heart pumps the oxygen-rich blood into the body through the  aorta  and many other arteries. Any part of the heart-lung blood circuit can become damaged or blocked, leading to pulmonary vascular disease. Causes of Pulmonary Vascular Disease The causes of pulmonary vascular disease vary according to which of the lung
Read more

Pseudotumor Cerebri (PTC), A/K/A Idiopathic Intracranial Hypertension (IIH)

Image
  Pseudotumor Cerebri (PTC), also known as Idiopathic Intracranial Hypertension (IIH), is a condition characterized by increased intracranial pressure without a detectable tumor or other cause. Symptoms: 1. Headaches (severe, frequent) 2. Vision changes (double vision, blurred vision) 3. Tinnitus (ringing in ears) 4. Hearing loss 5. Dizziness 6. Nausea and vomiting 7. Papilledema (swelling of optic disc) Causes and risk factors: 1. Obesity 2. Female gender (especially childbearing age) 3. Hormonal changes 4. Certain medications (e.g., tetracyclines, vitamin A derivatives) 5. Sleep apnea 6. Head trauma Diagnosis: 1. Lumbar puncture (LP) to measure cerebrospinal fluid (CSF) pressure 2. Imaging studies (MRI, CT scans) to rule out other causes 3. MR venogram or CT venogram of the head can be done to rule out a cerebral venous sinus thrombosis. A lumbar puncture (spinal tap) is done to measure the pressure of the cerebrospinal fluid unless something is seen on the MRI or CT scan indicati
Read more